With an effort of strengthening its services, Glaxo Smith Kline has announced a series of investments in the UK that approximately sum up to £200 million. These investments will support the company's production of antibiotic medicine and create a centre for pharmaceutical manufacturing innovation in the UK.
GSK also plans to set up a new facility that's dedicated to yoke innovative technologies with the prospective ability to transform the methods of manufacturing medicines.
New equipment and machinery will be updated in manufacturing units in Hertfordshire and Worthing Ware and Sussex.
The tentative preferred site for GSK's new centre is Ware, Hertfordshire (GSK already has manufacturing and R&D facilities here).
The new manufacturing facilities in Ware will be used to build and develop GSK's newest generation of inhaler devices (RelvarTM ElliptaTM inhaler) for respiratory diseases.
In Worthing, a new bulk sterile building and filling line will be built for the company's antibiotic medicine AugmentinTM, which is exported to 150 countries. A new centre for manufacturing innovation will be built, dedicated to transforming emerging science and technologies into practical manufacturing applications.
The technologies used in these centres use nano-technologies to create intelligent drug product formulations which minimise side-effects and enhance efficacy.
GSK had announced a £500 million last March that included building a new factory in Ulverston, Cumbria. This investment of £200 m is in addition to the earlier investment.
GSK also recently announced an investment of £25 million to expand its operations in Montrose to support the delivery of its new pipeline of medicines.